Lifestyle changes may be more important than drugs for mild hypertensionBMJ 2019; 364 doi: https://doi.org/10.1136/bmj.l571 (Published 15 February 2019) Cite this as: BMJ 2019;364:l571
- Rob Cook, clinical director1,
- Tara Lamont2,
- Rosie Martin,, clinical specialist1
- on behalf of the NIHR Dissemination Centre
- 1Bazian, Economist Intelligence Unit healthcare, London, UK
- 2Wessex Institute, University of Southampton, Southampton, UK
- Correspondence to R Cook
Sheppard JP, Stevens S, Stevens R, Martin U, Mant J, Hobbs R, McManus R. Benefits and harms of antihypertensive treatment in low-risk patients with mild hypertension.
Published on 1 December 2018 JAMA Intern Med 2018;178:1626-34.
This project was funded by a grant from the National Institute for Health Research (NIHR-RP-R2-12-O15) and the Medical Research Council (MRC) Strategic Skills Postdoctoral Fellowship.
To read the full NIHR Signal, go to: https://discover.dc.nihr.ac.uk/content/signal-000713/lifestyle-changes-for-mild-hypertension-rather-than-drugs
Competing interests The BMJ has judged that there are no disqualifying financial ties to commercial companies. The authors declare the following other interests: none.
Further details of The BMJ policy on financial interests is here: https://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/declaration-competing-interests
Contributors All authors contributed to development and review of this summary, as part of the wider NIHR Signals editorial team (https://www.bmj.com/NIHR-signals). RC is guarantor.
Disclaimer NIHR Signals are owned by the Department of Health and Social Care and are made available to the BMJ under licence. NIHR Signals report and comment on health and social care research but do not offer any endorsement of the research. The NIHR assumes no responsibility or liability arising from any error or omission or from the use of any information contained in NIHR Signals.
Permission to reuse these articles should be directed to firstname.lastname@example.org